Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3

Revenue Increased 113% During First Nine Months Of 2023

Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.

EMA
Aflibercept represents a significant market opportunity for Formycon

German biosimilars developer Formycon AG has submitted a marketing authorization application for FYB203, its Eylea (aflibercept) biosimilar candidate, to the European Medicines Agency. The application has been submitted in partnership with Klinge Biopharma, the exclusive owner of the global commercialization rights for FYB203.

Formycon CEO Stefan Glombitza said: “We are very pleased that with FYB203 we have filed our second biosimilar candidate in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.